ArticleBritish journal of pharmacology2007
Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusions.
Article in British journal of pharmacology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 98 citations in OpenAlex.
- Cannabinoid Receptors: An Update on Cell Signaling, Pathophysiological Roles and Therapeutic Opportunities in Neurological, Cardiovascular, and Inflammatory Diseases.International journal of molecular sciences · 2020Pooled it
- Safety of oral dronabinol during opioid withdrawal in humans.Drug and alcohol dependence · 2015Trial
- Article
- Potential of CBD Acting on Cannabinoid Receptors CBInternational journal of molecular sciences · 2024Review
- Potential perioperative cardiovascular outcomes in cannabis/cannabinoid users. A call for caution.Frontiers in cardiovascular medicine · 2024Review
- Applications of Cannabinoids in Neuropathic Pain: An Updated Review.Critical reviews in therapeutic drug carrier systems · 2024Review
- Cannabis and adverse cardiovascular events: A systematic review and meta-analysis of observational studies.Toxicology reports · 2023Article
- Pharmacognosy and Effects of Cannabinoids in the Vascular System.ACS pharmacology & translational science · 2022Review
- Serum Proteomic Analysis of Cannabis Use Disorder in Male Patients.Molecules (Basel, Switzerland) · 2021Article
- The Endocannabinoid System: A Potential Target for the Treatment of Various Diseases.International journal of molecular sciences · 2021Review
- Article
- Bibenzyls and bisbybenzyls of bryophytic origin as promising source of novel therapeutics: pharmacology, synthesis and structure-activity.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2020Review
- CYP2J2 Molecular Recognition: A New Axis for Therapeutic Design.Pharmacology & therapeutics · 2020Review
- Cross-talk of cannabinoid and endocannabinoid metabolism is mediated via human cardiac CYP2J2.Journal of inorganic biochemistry · 2018Article
- Anandamide and endocannabinoid system: an attractive therapeutic approach for cardiovascular disease.Therapeutic advances in cardiovascular disease · 2018Review
- The endocannabinoid system in cardiovascular function: novel insights and clinical implications.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2018Review
- Effects of the endogenous cannabinoid anandamide on voltage-dependent sodium and calcium channels in rat ventricular myocytes.British journal of pharmacology · 2014Article
- Cannabinoid receptor 1 signaling in cardiovascular regulating nuclei in the brainstem: A review.Journal of advanced research · 2014Review
- Cannabinoids and atherosclerotic coronary heart disease.Clinical cardiology · 2012Review
- Triphasic blood pressure responses to cannabinoids: do we understand the mechanism?British journal of pharmacology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In addition to their classical known effects, such as analgesia, impairment of cognition and learning and appetite enhancement, cannabinoids have also been related to the regulation of cardiovascular responses and implicated in cardiovascular pathology. Elevated levels of endocannabinoids have been related to the extreme hypotension associated with various forms of shock as well as to the cardiovascular abnormalities that accompany cirrhosis. In contrast, cannabinoids have also been associated with beneficial effects on the cardiovascular system, such as a protective role in atherosclerosis progression and in cerebral and myocardial ischaemia. In addition, it has also been suggested that the pharmacological manipulation of the endocannabinoid system may offer a novel approach to antihypertensive therapy. During the last decades, the tremendous increase in the understanding of the molecular basis of cannabinoid activity has encouraged many pharmaceutical companies to develop more potent synthetic cannabinoid analogues and antagonists, leading to an explosion of basic research and clinical trials. Consequently. not only the synthetic THC dronabinol (Marinol) and the synthetic THC analogue nabilone (Cesamet) have been approved in the United States, but also the standardized cannabis extract (Sativex) in Canada. At least three strategies can be foreseen in the future clinical use of cannabinoid-based drugs: (a) the use of CB(1) receptor antagonists, such as the recently approved rimonabant (b) the use of CB(2)-selective agonists, and (c) the use of inhibitors of endocannabinoid degradation. In this context, the present review examines the effects of cannabinoids and of the pharmacological manipulation of the endocannabinoid system, in cardiovascular pathophysiology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.